Early Experience With New Transcatheter Mitral Valve Replacement.

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Medical Devices

Background:

• Severe mitral regurgitation (MR) poses a significant clinical challenge.
• Transcatheter mitral valve replacement (TMVR) offers a potential therapeutic option for symptomatic patients.
• The feasibility of TMVR, particularly with novel valve systems, requires thorough investigation.

Purpose of the Study:

• To evaluate the early clinical experience and feasibility of a new self-expanding nitinol valve system for transcatheter mitral valve replacement (TMVR).
• To assess the safety and efficacy of TMVR in patients with symptomatic, severe mitral regurgitation who are at high or extreme risk for conventional surgery.

Main Methods:

• A global pilot study enrolled 50 high-risk patients with symptomatic severe MR.
• The investigational device was a self-expanding nitinol valve with bovine pericardial leaflets, delivered via a transapical system.
• Device implantation success, 30-day outcomes, and follow-up clinical and echocardiographic data were collected.

Main Results:

• Successful device implantation was achieved in 48 patients, with a median deployment time of 14 minutes.
• At 30 days, there was 14% mortality, but no disabling strokes or repeat interventions.
• At median follow-up of 173 days, all implanted patients had mild or no residual MR, with significant improvements in New York Heart Association functional class and quality of life.

Conclusions:

• Transcatheter mitral valve replacement (TMVR) using this novel valve system is feasible in high-risk patients with severe mitral regurgitation.
• The positive early outcomes support further investigation of TMVR in lower-risk patient populations.
• These findings provide valuable data for designing future TMVR trials.